A survey of gastroenterologists, dermatologists, and rheumatologists found Amjevita had the most recognition, followed by Cyltezo, the only interchangeable biosimilar on the US market. With ...

Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...

Please provide your email address to receive an email when new articles are posted on . AbbVie reported a worldwide net revenue of $12.31 billion and a 0.7% increase in its first quarter. Global net ...

Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of biosimilar competition, polling doctors about forces shaping the market and their ...

People taking adalimumab (Humira) for moderate-to-severe hidradenitis suppurativa (HS) saw better results across the board when the drug was combined with a surgical intervention. That's according to ...

Please provide your email address to receive an email when new articles are posted on . Adalimumab-adbm injection – a Humira biosimilar – is to be priced at 81% discount to Humira. Under the brand ...

For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. After all, at its peak, Humira brought in ...